Holger Hebart

11.5k total citations · 1 hit paper
146 papers, 6.7k citations indexed

About

Holger Hebart is a scholar working on Epidemiology, Oncology and Infectious Diseases. According to data from OpenAlex, Holger Hebart has authored 146 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 84 papers in Epidemiology, 37 papers in Oncology and 34 papers in Infectious Diseases. Recurrent topics in Holger Hebart's work include Cytomegalovirus and herpesvirus research (52 papers), Herpesvirus Infections and Treatments (32 papers) and Antifungal resistance and susceptibility (31 papers). Holger Hebart is often cited by papers focused on Cytomegalovirus and herpesvirus research (52 papers), Herpesvirus Infections and Treatments (32 papers) and Antifungal resistance and susceptibility (31 papers). Holger Hebart collaborates with scholars based in Germany, United States and Austria. Holger Hebart's co-authors include Hermann Einsele, Ulrike Schumacher, Gerhard Jahn, Jürgen Löffler, Hermann Einsele, Juergen Loeffler, Lothar Kanz, Christian Sinzger, Susanne Riegler and Ulrich Grigoleit and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Holger Hebart

142 papers receiving 6.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infusion of cytomegalovirus (CMV)–specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy

2002 559 citations Hermann Einsele, Christian Sinzger et al. profile →

Peers

Countries citing papers authored by Holger Hebart

Since Specialization

Citations

This map shows the geographic impact of Holger Hebart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Holger Hebart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Holger Hebart more than expected).

Fields of papers citing papers by Holger Hebart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Holger Hebart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Holger Hebart. The network helps show where Holger Hebart may publish in the future.

Co-authorship network of co-authors of Holger Hebart

This figure shows the co-authorship network connecting the top 25 collaborators of Holger Hebart. A scholar is included among the top collaborators of Holger Hebart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Holger Hebart. Holger Hebart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Tolerability and efficacy of deferasirox in patients with transfusional iron overload: results from a German 2-year non-interventional study 2018 ·Journal of Cancer Research and Clinical Oncology ·Florian Nolte, Holger Nückel, Burkhard Schmidt, Thomas Geer, (unknown), Holger Hebart, Andrea Jarisch, Stefan Albrecht, (unknown), Christiane Schumann, Wolf‐Karsten Hofmann	2
2	COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110) 2017 ·Haematologica ·Frank Stegelmann, Martin Grießhammer, Markus Bangerter, Holger Hebart, (unknown), (unknown), Nikolas von Bubnoff, Christof Scheid, (unknown), Steffen Koschmieder, Konstanze Doehner, Thomas Kindler, Andreas Reiter, Denise Wolleschak, Andreas Hochhaus, Florian H. Heidel, (unknown), Hartmut Doehner	2
3	Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia 2016 ·British Journal of Haematology ·Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, (unknown), Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger	30
4	Prospective comparison of PCR-based vs late mRNA-based preemptive antiviral therapy for HCMV infection in patients after allo-SCT 2010 ·Bone Marrow Transplantation ·Holger Hebart, Claudia Lengerke, Per Ljungman, C. V. Paya, Thomas Klingebiel, Juergen Loeffler, (unknown), Ilona Lewensohn‐Fuchs, Lisbeth Barkholt, Jürgen Tomiuk, C Meisner, (unknown), Bert Top, Raymund R. Razonable, Robin Patel, Mark R. Litzow, Gerhard Jahn, Hermann Einsele	16
5	Dendritic Cell Vaccination in Allogeneic Stem Cell Recipients: Induction of Human Cytomegalovirus (HCMV)–Specific Cytotoxic T Lymphocyte Responses Even in Patients Receiving a Transplant from an HCMV‐Seronegative Donor 2007 ·The Journal of Infectious Diseases ·Götz Ulrich Grigoleit, Markus Kapp, Holger Hebart, (unknown), Robert Beck, Gerhard Jahn, Hermann Einsele	46
6	Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains 2006 ·FEMS Microbiology Letters ·Jürgen Löffler, Steven L. Kelly, Holger Hebart, Ulrike Schumacher, Cornelia Lass‐Flörl, Hermann Einsele	77
7	Evaluation of the COBAS Amplicor HCMV Monitor for early detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation 2006 ·Bone Marrow Transplantation ·Claudia Lengerke, (unknown), C Meisner, Juergen Loeffler, Christian Sinzger, Hermann Einsele, Holger Hebart	13
8	Antiviral prophylaxis in patients with haematological malignancies and solid tumours: Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO) 2006 ·Annals of Oncology ·Michael Sandherr, Hermann Einsele, Holger Hebart, Christoph Kahl, Winfried V. Kern, Michael Kiehl, Gero Massenkeil, Olaf Penack, Xaver Schiel, (unknown), Andrew J. Ullmann, Oliver A. Cornely	72
9	CMV-specific immunotherapy 2004 ·Human Immunology ·Hermann Einsele, Holger Hebart	25
10	Clinical aspects of cmv infection after stem cell transplantation 2004 ·Human Immunology ·Holger Hebart, Hermann Einsele	107
11	A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation 2003 ·Experimental Hematology ·Holger Hebart, Georg Rauser, Stefan Stevanović, (unknown), Alexander K. Nussbaum, Christoph Meisner, Alfred Lennart Bissinger, Stefan Tenzer, Gerhard Jahn, Juergen Loeffler, Hans‐Georg Rammensee, Hansjörg Schild, Hermann Einsele	18
12	Follow‐up of patients with progressive multiple myeloma undergoing allografts after reduced‐intensity conditioning 2003 ·British Journal of Haematology ·Hermann Einsele, (unknown), Holger Hebart, Peter Bader, Christoph Meisner, Ludwig Plaßwilm, Peter Liebisch, Michael Bamberg, Christoph Faul, Lothar Kanz	82
13	Quantification of T-cell receptor excision circle DNA using fluorescence resonance energy transfer and the LightCycler system 2002 ·Journal of Immunological Methods ·Juergen Loeffler, R. Bauer, Holger Hebart, Daniel C. Douek, Georg Rauser, Peter Bader, Hermann Einsele	17
14	Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation 2002 ·Bone Marrow Transplantation ·Holger Hebart, (unknown), Juergen Loeffler, Jaap M. Middeldorp, (unknown), Gerhard Jahn, Hermann Einsele	19
15	Epidemiologie und interventionelle Therapiestrategien infektiöser Komplikationen nach allogener Stammzelltransplantation 2001 ·DMW - Deutsche Medizinische Wochenschrift ·Hermann Einsele, Hartmut Bertz, J. Beyer, (unknown), Volker Runde, H. J. Kolb, Ernst Holler, Rose Beck, (unknown), U. Schumacher, Holger Hebart, (unknown), J Kienast, (unknown), Georg Maschmeyer, William Krüger, Hartmut Link, (unknown), Helmut Oettle, (unknown)	5
16	Molecular methods in the diagnosis of infections in the immunocompromised host 2000 ·Current Opinion in Infectious Diseases ·Holger Hebart, Juergen Loeffler, Lothar Kanz, Hermann Einsele	3
17	New Aspects for the Diagnosis of Invasive Fungal Disease in Oncological Patients 1997 ·Oncology Research and Treatment ·Holger Hebart, C. Bokemeyer, Jürgen Löffler, Ulrike Schumacher, Lothar Kanz, H. Einsele	2
18	Cytomegalovirus Monitoring by Polymerase Chain Reaction of Whole Blood Samples from Patients Undergoing Autologous Bone Marrow or Peripheral Blood Progenitor Cell Transplantation 1997 ·The Journal of Infectious Diseases ·Holger Hebart, Arne Schröder, Jürgen Löffler, Thomas Klingebiel, (unknown), Barbara Waßmann, (unknown), Holger F. Rabenau, Gerhard Jahn, Lothar Kanz, C A Müller, Hermann Einsele	37
19	ENDOGENOUS INTERLEUKIN 1 RECEPTOR ANTAGONIST DURING HUMAN BONE MARROW TRANSPLANTATION 1997 ·Transplantation ·H Schwaighofer, (unknown), Holger Hebart, (unknown), M. Herold, David Nachbaur, Brigitte Eibl, (unknown), Gabriele Kropshofer, James L.M. Ferrara, D Niederwieser	13
20	Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease 1997 ·Bone Marrow Transplantation ·Hans Krause, Holger Hebart, Gerhard Jahn, Müller Ca, Hermann Einsele	127

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact